Logo

MitoSciences Licenses Antibody Tech for Cell-based Screening

Apr 16, 2008
NEW YORK (GenomeWeb News) – MitoSciences has agreed to an exclusive license for monoclonal antibodies from the University of Oregon for use in its cell-based drug toxicity screening tests and multiplexing assays, the Eugene, Ore.-based company said today.
 
The University will receive royalties from patent-related sales and $4.6 million in fixed quarterly cash payments over 10 years.
 
The agreement also gives MitoSciences exclusive commercialization rights for a portfolio of “biological assets,” and an exclusive license for several patents covering the use of monoclonal antibodies that recognize mitochondrial antigens, the company said.

Breaking News
The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.